| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4589525
Max Phase: Preclinical
Molecular Formula: C21H19FN6O2
Molecular Weight: 406.42
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: O=C(O)[C@H]1C2CCC(CC2)[C@@H]1n1cnc2cnc(-c3c[nH]c4ncc(F)cc34)nc21
Standard InChI: InChI=1S/C21H19FN6O2/c22-12-5-13-14(7-24-18(13)23-6-12)19-25-8-15-20(27-19)28(9-26-15)17-11-3-1-10(2-4-11)16(17)21(29)30/h5-11,16-17H,1-4H2,(H,23,24)(H,29,30)/t10?,11?,16-,17-/m0/s1
Standard InChI Key: RSBRJNASPIIEKH-VOGSPBGVSA-N
Associated Targets(non-human)
Polymerase basic protein 2 86 Activities
MDCK 10148 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 406.42 | Molecular Weight (Monoisotopic): 406.1554 | AlogP: 3.57 | #Rotatable Bonds: 3 |
| Polar Surface Area: 109.58 | Molecular Species: ACID | HBA: 6 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 4.32 | CX Basic pKa: 1.87 | CX LogP: 3.00 | CX LogD: 0.03 |
| Aromatic Rings: 4 | Heavy Atoms: 30 | QED Weighted: 0.54 | Np Likeness Score: -0.47 |
References
| 1. Xiong J, Wang J, Hu G, Zhao W, Li J.. (2019) Design, synthesis and biological evaluation of novel, orally bioavailable pyrimidine-fused heterocycles as influenza PB2 inhibitors., 162 [PMID:30448415] [10.1016/j.ejmech.2018.11.015] |
Source
Source(1):